Metastatic Non-small Cell Lung Cancer (NSCLC), Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non Small Cell Lung Cancer Stage III, Small-cell Lung Cancer
Conditions
Brief summary
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
Detailed description
Thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and outcome of unselected patients in real-life practice, is crucial to evaluate and improve the quality of care for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The purpose of CRISP is to set up a national clinical research platform to document uniform data on the molecular testing, treatment, course of disease in patients with NSCLC or SCLC. A particular focus is on molecular biomarker testing before the start of first-line treatment of patients with advanced or metastatic NSCLC. The data shall be used to assess the current state of care and to develop recommendations concerning topics that could be improved. PRO assessment will provide large-scale data on quality of life and anxiety/depression for real-life patients with NSCLC or SCLC in routine practice. In addition, two questionnaires (concerning individual quality of life and patient-caregiver communication) will be validated in German patients with metastatic NSCLC. Furthermore, CRISP will set up a decentralized clinically annotated tissue repository for future collaborative, investigational scientific biomarker testing.
Interventions
OTHERdata collection
Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
Sponsors
AstraZeneca
Celgene Corporation
Merck Sharp & Dohme LLC
Novartis Pharmaceuticals
Pfizer
Boehringer Ingelheim
Bristol-Myers Squibb
iOMEDICO AG
Eli Lilly and Company
Roche Pharma AG
Takeda
Amgen
Janssen-Cilag G.m.b.H
GlaxoSmithKline
Daiichi Sankyo
Regeneron Pharmaceuticals
Gilead Sciences
AIO-Studien-gGmbH
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients who meet all of the following criteria are eligible for the project: * Age ≥ 18 years * Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments Main project (Metatstatic NSCLC): * Confirmed non-small cell lung cancer (NSCLC) * Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving best supportive care only * Stage IV, or stage IIIB/C (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy * Systemic therapy or best supportive care Satellite Stage I/II/III (NSCLC): * Confirmed non-small cell lung cancer (NSCLC) * Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving best supportive care only (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy) * Stage I, Stage II, stage IIIA, or stage IIIB/C (UICC8) * Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care Satellite SCLC * Confirmed Small cell lung cancer (SCLC) * Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving best supportive care only (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy) * Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
Exclusion criteria
none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| biomarker | 3 years | To collect data on the frequency, methodology and results of molecular biomarker testing before first-line and later-line treatment |
| treatment | 3 years | To describe systemic treatments and sequential treatments applied in real-life practice |
| Response rate | 3 years | To assess effectiveness of systemic treatments in regards to response rate. |
| progression free survival | 3 years | To assess effectiveness of systemic treatments in regards to progression free survival. |
| overall survival | 3 years | To assess effectiveness of systemic treatments in regards overall survival. |
| physician-reported factors | 3 years | To describe physician-reported factors affecting treatment decision making besides biomarker profiling |
| supportive therapies | 3 years | to collect key data on specific supportive therapies |
| changes during the project | 3 years | To investigate changes in diagnostics, treatment or outcome during the course of the project |
| general health-related and individual quality of life (QoL) patient-reported outcomes | 3 years | To evaluate patient-reported outcomes concerning (1) general health-related and individual quality of life (QoL). and depression, (4) patient-caregiver communication |
| physical and psychological well-being patient-reported outcomes | 3 years | To evaluate patient-reported outcomes concerning physical and psychological well-being. |
| anxiety patient-reported outcomes | 3 years | To evaluate patient-reported outcomes concerning anxiety. |
Countries
Germany
Contacts
Primary ContactAnnika Groth
Backup ContactPaula Ludwig
Outcome results
None listed